Canada Diabetes Care Drugs and Devices Market | Industry Analysis (2022-27)

 

Market Overview

Canada Diabetes Care Drugs and Devices Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027.

Canada has 107,861 cases of coronavirus disease 2019 (COVID-19) (286 per 1,00,000 individuals) and 8787 COVID-19-related fatalities as of July 13, 2020. In Canada, public health is overseen at the federal, provincial, and regional levels, and the Canadian constitution delegates healthcare authority to the country's ten provinces and three territories. As a result, similar to the United States, where individual states generally defined the COVID-19 response, Canadian provinces have mostly selected containment and mitigation plans. Provincial public health authorities collaborated closely with regional public health officers and municipal governments to develop policies and recommendations, as well as to put services like testing and contact tracing in place. Blood pressure regulation is a critical component of diabetes management. Furthermore, even in the absence of high blood pressure, certain blood pressure lowering medications are frequently recommended for people living with diabetes to protect them from kidney and heart-related complications. There is currently no scientific evidence linking these blood pressure drugs to the likelihood of COVID-19 infection or associated consequences.

In Canada, During the pandemic, many healthcare providers have adopted a hybrid model of care, offering certain types of visits in-person at the clinic and others virtually, by phone, video chat, or secure messaging. Virtual diabetes care may be a new and different experience for you. For tips on preparing for your diabetes visit and managing virtual appointments.

Scope of the Report

Canada Diabetes Care Drugs and Devices Market is expected to register a CAGR greater than 4% over the forecast period, 2022-2027. The Canada Diabetes Care Drugs and Devices Market The market is segmented by Drugs (by Category (Insulin, Oral Anti-Diabetic Drugs, Non-Insulin Injectable Drugs, and Combination Drugs), by sub-segment (Basal or Long-acting, Bolus or Fast-acting, Traditional Human Insulin Drugs, Insulin Biosimilars, GLP-1 Receptor Agonists, Alpha-Glucosidase Inhibitors, DPP-4 Inhibitors, and SGLT-2 Inhibitors)) and Devices ( Management Devices (Insulin Pumps, Insulin Pens, Syringes, Cartridges, and Jet Injectors) and Monitoring Devices (Self-monitoring Blood and Continuous Glucose Monitoring)). The report offers the value (in USD million) for the above segments.

Read Full Report

Comments

Popular Posts

Aviation Industry Set to Soar: Market to Hit USD 395.76 Billion by 2030 Amid Stable Growth

Recreational Boating Market Set to Reach USD 36.82 Billion by 2030: Key Growth Drivers and Trends

Kuwait Dairy Products Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Coffee Machine Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)